Androgenetic Alopecia: Understanding the Most Common Form of Hair Loss

Androgenetic alopecia — commonly referred to as male or female pattern hair loss — is the most prevalent form of hair loss in the world, affecting approximately 50 million men and 30 million women in the United States alone. Despite its extraordinary prevalence, it remains widely misunderstood: many patients assume it is untreatable or inevitable, delaying evaluation until follicular loss has progressed well beyond the optimal treatment window.

At Regen Health Physicians NYC, Dr. Ajit Dhaliwal and our clinical team have made the diagnosis and treatment of androgenetic alopecia a core component of our precision hair restoration program. Understanding the condition is the first step toward doing something about it.

What Is Androgenetic Alopecia?

Androgenetic alopecia (AGA) is a genetically mediated, androgen-dependent condition in which genetically susceptible hair follicles respond to dihydrotestosterone (DHT) — a potent androgen derived from testosterone via the enzyme 5-alpha reductase — by progressively miniaturizing. Miniaturization is the process by which a full terminal hair follicle gradually produces shorter, thinner, lighter hairs over successive growth cycles, until the follicle enters a permanently dormant state.

The process is:

• Genetic: Multiple gene loci, including the androgen receptor gene on the X chromosome, determine follicular sensitivity to DHT
• Androgen-dependent: DHT is the primary driver. Follicles in the front and top of the scalp (in men) and the crown (in women) are genetically predisposed to DHT sensitivity
• Progressive: Without intervention, miniaturization continues over years to decades
• Reversible in early stages: This is the most clinically important point — miniaturized follicles can be rescued. Completely absent follicles cannot.

How AGA Presents in Men vs. Women

Male Pattern Hair Loss (MPHL)

The Hamilton-Norwood scale categorizes male pattern hair loss in seven stages:

• Type I: Minimal recession at the temples; barely perceptible
• Type II: Slight recession of the hairline at the temples
• Type III: Clear temporal recession; beginning of significant change
• Type III Vertex: Thinning at the crown (vertex) begins
• Type IV: Significant hairline recession + crown thinning
• Type V–VII: Progressive merger of frontal and vertex loss into extensive baldness

The most common initial presentation is bilateral temporal recession — often first noticeable in the mid-20s to 30s — followed by crown thinning.

Female Pattern Hair Loss (FPHL)

The Ludwig scale describes female pattern hair loss:

• Type I: Diffuse thinning across the crown with preserved hairline
• Type II: Widening of the central part with visible scalp
• Type III: Significant diffuse thinning with visible scalp through the crown

Women with FPHL rarely experience complete baldness but can experience significant volume and density loss that is cosmetically and psychologically significant. Crucially, the hormonal picture in women with AGA is more complex — estrogen, progesterone, thyroid function, and insulin sensitivity all interact with androgenic hair follicle sensitivity.

Diagnosing Androgenetic Alopecia Properly

While AGA is the most common diagnosis, other conditions can mimic or co-occur with it. A thorough evaluation is essential.

At RHPNY, our hair loss workup includes:

Scalp dermoscopy: Magnified visualization of the scalp to assess follicular miniaturization, perifollicular fibrosis, and hair shaft caliber variation — the hallmarks of AGA — versus the patchy loss of alopecia areata or the scarring fibrosis of lichen planopilaris.

Hormonal panel: TSH, free T3/T4, testosterone (total and free), DHEA-S, prolactin, LH/FSH, estradiol (in women). Hormonal contributors to hair loss must be identified and addressed.

Nutritional markers: Ferritin, zinc, vitamin D, B12. Iron deficiency — particularly low ferritin — is among the most commonly missed contributors to hair shedding and may co-occur with AGA.

Inflammatory markers: Scalp inflammation is an independent accelerant of follicular miniaturization; chronic scalp inflammation requires treatment alongside AGA-specific interventions.

This breadth of evaluation allows Dr. Dhaliwal to identify all contributing factors — not just AGA in isolation — and design a protocol that addresses the complete picture.

Treatment Approach at RHPNY

The most important treatment principle in AGA is early intervention. The treatment window is open while miniaturized follicles remain. Rescue becomes progressively more difficult as miniaturization advances, and impossible once follicles are completely lost.

PRP Hair Restoration Therapy

PRP (Platelet-Rich Plasma) therapy is the cornerstone of our hair restoration program and the treatment with the strongest evidence base for AGA reversal in both men and women. PRP delivers a concentrated mixture of growth factors — PDGF, VEGF, IGF-1, TGF-β — directly to the scalp, extending the anagen (growth) phase, improving follicular blood supply, and reversing early miniaturization.

Clinical studies demonstrate statistically significant improvements in hair density, shaft diameter, and hair count after a series of three PRP sessions. The results are dose-dependent: the earlier treatment begins, and the more faithfully the protocol is followed, the better the outcomes.

Medical Adjuncts

Several evidence-supported medical adjuncts can be integrated into AGA treatment:

• Topical minoxidil (2–5%): Extends the anagen phase through mechanisms partially distinct from PRP; useful as a maintenance complement
• Oral finasteride or dutasteride (in men): 5-alpha reductase inhibitors that reduce systemic DHT; highly effective for slowing AGA progression; prescribed with discussion of risk/benefit profile
• Topical finasteride: Lower systemic DHT reduction with comparable scalp-level effect; favorable tolerability profile
• Low-level laser therapy (LLLT): Photobiomodulation that supports follicular ATP production and cellular activity; used as an adjunct in motivated patients

Nutritional and Hormonal Optimization

Correcting ferritin deficiency, optimizing vitamin D and zinc, normalizing thyroid function, and addressing hormonal contributors (particularly in women) often produces meaningful improvement in hair shedding and quality — sometimes dramatically so.

Our chronic disease management and hormone program integrates these components into hair restoration protocols for patients with systemic contributors.

Peptide Therapy Adjuncts

Select peptides with tissue repair, anti-inflammatory, and hormonal-supportive properties may be incorporated into comprehensive hair restoration protocols for appropriate patients — particularly those with co-existing systemic concerns.

What Results Are Realistic?

With early intervention and adherence to protocol, most patients with AGA can:

• Arrest or significantly slow progressive miniaturization
• Recover meaningful density in areas of early to moderate thinning
• Achieve natural-looking improvement that does not require disclosure

The realistic expectation is stabilization and improvement — not a return to 20-year-old hair density. Managing expectations honestly is a core commitment at RHPNY. We will tell you what is genuinely achievable for your specific presentation.

Take Action While the Window Is Open

If you have noticed hair thinning, a receding hairline, widening part, or reduced ponytail diameter, the most important thing you can do is act now. The earlier we intervene, the more hair we can preserve and recover.

Book a hair restoration consultation with Dr. Dhaliwal at RHPNY. We serve patients across New York City and Salt Lake City and offer both in-person and telehealth evaluation for initial workup.

---

Medical Disclaimer: Androgenetic alopecia requires individual medical evaluation and treatment planning. Results of PRP and medical hair loss treatments vary based on degree of hair loss, genetics, and adherence to protocol. This content is for informational purposes only and does not constitute medical advice.